Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial https://pubmed.ncbi.nlm.nih.gov/38302221/
参考文献 Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv (2021) 5 (...
Life Beyond RVD: The Future of Induction Therapy for Multiple Myeloma - ScienceDirectcellular-based therapyimmunotherapyinduction therapyMMmultiple myelomaproteasome inhibitorsdoi:10.1016/j.clml.2019.07.404Amrita Krishnan MDClinical Lymphoma Myeloma and Leukemia...
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial https://pubmed.ncbi.nlm.nih.gov/37708911/...
Voorhees PM,et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase ...
作为中国首个获批的CD38单克隆抗体靶向药物,这一革新的方案有望再定义国内多发性骨髓瘤的治疗。 原文出处:Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
原文出处:Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN 原标题:一线治疗符合干细胞移植的新诊多发性骨髓瘤!强生Darzalex(兆珂®)+RVd方案展现强劲疗效!
New 3-drug combo may effectively treat multiple myeloma RVD took on Shelton Benjamin for the Intercontinental Championship and looked to have it in the bag until a cheap shot by Shelton Benjamin meant the ref couldn't see him holding onto the ropes while he pinned RVD. Revenge is sweet in ...
“The prognosis for patients with multiple myeloma has improved substantially over the last 10 years,” said ASCO chief medical officer and executive vice president Julie R. Gralow, MD, FACP, FASCO, said during a press briefing. “This trial gives very important inf...
Jakubowiak et al recently published promising results from a phase 1/2 study evaluating the second-generation proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone (CRd) for the treatment of newly diagnosed multiple myeloma.1 Encouragingly, only 23% of patients experienced ...